Deal Making

Featured on Deal Making

Roche licenses cell line-based AAV vector tech from CEVEC
Deal-Making
Roche licenses cell line-based AAV vector tech from CEVECRoche licenses cell line-based AAV vector tech from CEVEC

Roche will access an adeno-associated virus (AAV) vector manufacturing platform in a deal CEVEC says validates its ELEVECTA technology.

More from Deal Making